Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | AGXT | P21549 | 2/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766421 | 0.83 | TAAR1 (0.57) | TAAR1IDO1AGXTCMA1MEN1 | |
| SCHEMBL11743064 | 0.81 | ALDH1A1 (0.46) | MEN1ALDH1A1POLBMAPTKMT2A | |
| SCHEMBL9321479 | 0.80 | TSHR (0.45) | ALDH1A1FBP1CYP1A2 | |
| SCHEMBL13924713 | 0.79 | ALOX5 (0.43) | MEN1ALDH1A1POLBMAPTCRHBP | |
| SCHEMBL11226363 | 0.79 | TLR4 (0.58) | MEN1MAPTKMT2A | |
| SCHEMBL11742933 | 0.78 | MAOB (0.59) | MAOB | |
| SCHEMBL3023265 | 0.78 | DAO (0.50) | MEN1MAPTKMT2ADAO | |
| SCHEMBL3023462 | 0.78 | CHRM2 (0.51) | CHRM2CHRM1CHRM3DAOMAOB | |
| SCHEMBL1341462 | 0.78 | AR (0.45) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL9323722 | 0.77 | IDO1 (0.48) | TAAR1IDO1AGXTCMA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015184383-A1 | ARYL-SUBSTITUTED IMIDAZOLES AND METHODS OF MAKING AND USING SAME | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2015-12-03 | — | — | WO | disclosed |
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2391603-B1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2391603-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| US-4202991-A | Novel bicycloalkane derivatives and the production thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-05-13 | — | — | US | disclosed |
| US-4072716-A | Bicycloalkane derivatives | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-02-07 | — | — | US | disclosed |
| US-4064173-A | 9,10-Seco-steroids | HOFFMANN-LA ROCHE, INC. (US) | 1977-12-20 | — | — | US | disclosed |
| US-4051188-A | NOVEL BICYCLOALKANE DERIVATIVES AND THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
| US-4045490-A | 9,10-Seco-steroid preparation | HOFFMANN-LA ROCHE INC. (US) | 1977-08-30 | — | — | US | disclosed |
| US-4008253-A | Bicycloalkanes | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | TAAR1 82/4885IDO1 605/4885AGXT 2855/4885 |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | TAAR1 82/4885IDO1 605/4885AGXT 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.